One proven formulation with long-term outcomes

IN.PACT™ Admiral™* continues to demonstrate long-term clinical outcomes, even in patients considered to be at high risk of restenosis and repeat interventions.

With > 500,000 patients treated worldwide, IN.PACT™ Admiral™* has the proven safety and efficacy your patients deserve.

IN.PACT™ Admiral™* DCB** has the:

 

through three years compared to PTA†1

 

with 75% of patients reintervention free through five years1

 

for a DCB‡

 

*Third-party brands are trademarks of their respective owners.
†Primary patency not assessed after three years.
‡Data on file UC202013694cEE at Medtronic. https://europe.medtronic.com/content/dam/medtronic-com/xd-en/hcp/documents/digitalhub/cardiovascular/pvh/going-long-dcb/DCB_landscape_revision.pdf.

 

References

1.

Laird JA, Schneider PA, Jaff MR, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. 5-year results from the IN.PACT SFA Trial. Circ Cardiovasc Interv. June 2019;12(6):e007702. https://europe.medtronic.com/xd-en/c/emea/cardiovascular/inpact-admiral-reintervention-data.html

 

2.

Tepe G. 5-year results from the IN.PACT Global Study Prespecified Cohorts: ISR, CTO and Long Lesions. Presented at VIVA, 2021.

 

** The approved product name for the drug-coated balloon is IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter.
See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.

 

Adjust your preferences to ensure you receive communications in the subjects that interest you from Medtronic.

UC202402817 EE-cirse-pre-congress-eblast-for-pad-en-emea-10166527 © 2023 Medtronic. All rights reserved.